Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

CARET, THE BETA-CAROTENE AND RETINOL EFFICACY TRIAL TO PREVENT LUNG-CANCER IN ASBESTOS-EXPOSED WORKERS AND IN SMOKERS ANTI-CANCER DRUGS Omenn, G. S., Goodman, G., Grizzle, J., Thornquist, M., Rosenstock, L., Barnhart, S., Anderson, G., Balmes, J., Cherniack, M., Cone, J., Cullen, M., Glass, A., Keogh, J., Meyskens, F., Valanis, B. 1991; 2 (1): 79-86

Abstract

CARET is a two-armed, double-blind, randomized chemo-prevention trial to test the hypothesis that oral administration of beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day will decrease the incidence of lung cancer in high-risk populations: heavy smokers and asbestos-exposed workers who have smoked. The agents combine anti-oxidant and nuclear tumor suppressor mechanisms. Fastidious monitoring for possible side effects is facilitated by inclusion of a Vanguard population. As of 31 December 1990, 6,105 participants of the 18,000 needed have been randomized in the trial. Efficacy results are expected in 1999.

View details for Web of Science ID A1991FY07400011

View details for PubMedID 1958856